# EDGAR Filing Document

**Accession Number:** 0001435049
**File Stem:** 0001209191-23-006054
**Filing Date:** 2023-2
**Character Count:** 8767
**Document Hash:** d5a6b66f43a7f82636dde83869024e5b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-006054.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0001209191-23-006054

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230130

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230201

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** DOBMEIER ERIC
- **CENTRAL INDEX KEY:** 0001202785

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37345
- **FILM NUMBER:** 23578459

**MAIL ADDRESS:**
- **STREET 1:** C/O SAETTLE GENETICS INC
- **STREET 2:** 21823 30TH DRIVE SE
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98021
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHINOOK THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001435049
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 400 FAIRVIEW AVENUE NORTH, SUITE 900
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109
- **BUSINESS PHONE:** 206-485-7051

**MAIL ADDRESS:**
- **STREET 1:** 400 FAIRVIEW AVENUE NORTH, SUITE 900
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADURO BIOTECH, INC.
- **DATE OF NAME CHANGE:** 20111107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADURO BIOTECH
- **DATE OF NAME CHANGE:** 20080514

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>DOBMEIER ERIC<br><sub>(Last) (First) (Middle)</sub><br>C/O CHINOOK THERAPEUTICS, INC.<br>400 FAIRVIEW AVE. NO., 9TH FLOOR<br><sub>(Street)</sub><br>SEATTLE, WA 98109<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President, CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CHINOOK THERAPEUTICS, INC. [ KDNY ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-30 |  | M |  | 25000 | A | $0.42 | 296676 | D |  |
| Common Stock | 2023-01-30 |  | S<sup>(1)</sup> |  | 25000 | D | 24.5445<sup>(2)</sup> | 271676 | D |  |
| Common Stock | 2023-01-31 |  | M |  | 24999 | A | <sup>(3)</sup> | 296675 | D |  |
| Common Stock | 2023-01-31 |  | S |  | 7688<sup>(4)</sup> | D | $24.6822 | 288987 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $0.42 | 2023-01-30 |  | M |  |  | 25000 | <sup>(5)</sup> | 2030-03-17 | Common Stock | 25000 | $0.00 | 338555 | D |  |
| Stock Option (Right to Buy) | $25.27 | 2023-01-31 |  | A |  | 255150 |  | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 255150 | $0.00 | 255150 | D |  |
| Restricted Stock Unit | <sup>(7)</sup> | 2023-01-31 |  | A |  | 64050 |  | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 64050 | $0.00 | 64050 | D |  |
| Restricted Stock Unit | <sup>(7)</sup> | 2023-01-31 |  | M |  |  | 24999 | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 24999 | $0.00 | 50001 | D |  |

---

### Footnotes:

(1) The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.27 to $24.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

(3) Restricted stock units (RSUs) convert into common stock on a one-for-one basis.

(4) Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

(5) The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

(6) The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

(7) Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

(8) The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.

(9) The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.

**Signature:** /s/ Kirk Schumacher, Attorney-in-Fact  
**Date:** 2023-02-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**